Humanetics Corporation Email Format

Pharmaceutical ManufacturingMinnesota, United States11-50 Employees

Humanetics Corporation is a privately held, clinical-stage pharmaceutical company based in the Minneapolis metropolitan area. Its lead candidate, BIO 300, is being developed to enhance the efficacy of radiation therapy for solid tumor cancers while protecting normal tissues, with the aim of reducing related side effects.

BIO 300 is also under development for inflammatory lung diseases, including mitigation of pulmonary injury from COVID-19, with ongoing investigation of a phase 2 study in recovering patients. The program originated under a license from the U.S. Department of Defense, where it was developed to prevent injuries from ionizing radiation and the work continues toward preventing acute radiation syndrome and lung injury. In recent developments, the company announced plans to present at the 2026 Military Health System Research Symposium.

Get verified Humanetics Corporation emails free

Company overview Employee directory